The main objective of our study is to investigate the metabolic effects of whey protein (whey protein isolate, WPI, (Lacprodan® ISO.Water. from Arla Foods Ingredients) compared to placebo when consumed by women in risk of gestational diabetes mellitus (GMD) 30 minutes prior to an oral glucose tolerance test (OGTT). We will also investigate any changes in substrate metabolism and energy expenditure using indirect calorimetry. Differences in hunger and satiety parameters as well as rate of gastric emptying will also be assessed. Furthermore, we will investigate the glucose response when the women consume the intervention at home in their own environment 30 minutes before breakfast in various doses (placebo, 10, 15, 20, 30 g whey). The women will be monitored with continuous glucose monitors, activity monitors and all meals will be provided. The two study days in the laboratory will be repeated 3-9 months after pregnancy. The purpose of this is to be able to compare the metabolic response of pre-meal whey during pregnancy with the response in a not-pregnant state. The study days at home will not be repeated after pregnancy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
24
Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital
Aarhus, Denmark
Concentration differences in blood glucose following an OGTT
Time frame: 3 hours following the OGTT
Concentration differences in glucose independent peptide (GIP)
Time frame: 3 hours following the OGTT
Concentration differences in glucagon like peptide 1 (GLP-1)
Time frame: 3 hours following the OGTT
Concentration differences in glucagon
Time frame: 3 hours following the OGTT
Concentration differences in insulin
Time frame: 3 hours following the OGTT
Concentration differences in c-peptide
Time frame: 3 hours following the OGTT
Concentration differences in free fatty acids (FFA)
Time frame: 3 hours following the OGTT
Concentration differences in ghrelin
Time frame: 3 hours following the OGTT
Concentration differences in leptin
Time frame: 3 hours following the OGTT
Concentration differences in amino acids (AA)
Time frame: 3 hours following the OGTT
Gastric emptying rate (Concentration differences in blood paracetamol/acetaminophen)
Time frame: 3 hours following the OGTT
Resting energy expenditure (REE) (Resting Metabolic Rate)
Time frame: 3 hours following the OGTT
Respiratory quotient (RQ)
Time frame: 3 hours following the OGTT
Self-reported appetite
A visual analogue scale ranging from "not at all" to "extremely" will be used to assess Hunger, Fullness, Satiety, Desire, Prospective consumption (Quantity).
Time frame: 3 hours following the OGTT and 3 hours following breakfast
Heart rate
A combined accelerometer and heart rate monitor will be used to measure heart rate (beats/minute)
Time frame: 5 days
Energy expenditure
A combined accelerometer and heart rate monitor will be used to estimate energy expenditure (kCal)
Time frame: 5 days
Activity
A combined accelerometer and heart rate monitor will be used to measure activity (counts/minute)
Time frame: 5 days
Continuous glucose measurements (CGM)
Time in range, concentration differences in interstitial fluid glucose 3 hours following breakfast, glycemic variability, mean glucose, daily maximum glucose, estimated HbA1c
Time frame: 5 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.